Insmed Incorporated said that a just-closed public stock offering generated net proceeds of about $235.5 million that will be used for continuing commercialization of Arikayce amikacin liposome inhalation suspension (ALIS). The offering of 9,615,385 shares of common stock at $26.00/share resulted in gross proceeds of about $250 million. The underwriters of the … [Read more...] about Insmed raises $250 million in public stock offering
Business
According to Vectura and Sosei, Novartis has filed MAA for triple therapy DPI
Vectura Group and Sosei Group each said that they are owed $2.5 million milestone payments from Novartis after the EU accepted Novartis's MAA for its QVM149 indacaterol/glycopyrronium/mometasone furoate DPI for the treatment of asthma that is inadequately controlled. Vectura said that approval of the MAA would trigger an additional milestone payment of $5 million. … [Read more...] about According to Vectura and Sosei, Novartis has filed MAA for triple therapy DPI
AMSL Diabetes to distribute Afrezza inhaled insulin in Australia
MannKind Corporation has announced that signed a marketing and distribution agreement with Australasian Medical & Scientific Ltd division AMSL Diabetes for commercialization of Afrezza inhaled insulin in Australia. AMSL Diabetes will take responsibility for getting Australian regulatory and reimbursement approval for Afrezza and for sales, marketing, and … [Read more...] about AMSL Diabetes to distribute Afrezza inhaled insulin in Australia
Pneuma Respiratory licenses mAbs from Leads Biolabs for development of inhaled immuno-oncology therapy
Pneuma Respiratory has announced a licensing agreement with Nanjing Leads Biolabs subsidiary Leads Biolabs, Inc. for rights to develop Leads monoclonal antibodies and fusion protein molecules for delivery using Pneuma's digital soft mist inhaler. Pneuma said that it plans to develop inhaled immuno-oncology drugs. Pneuma Respiratory CEO and Co-Founder Eric Hunter … [Read more...] about Pneuma Respiratory licenses mAbs from Leads Biolabs for development of inhaled immuno-oncology therapy
Milestone Pharmaceuticals raises $82.5 million in IPO
Etripamil developer Milestone Pharmaceuticals announced that its recently closed initial public offering raised approximately $82.5 million gross by selling 5,500,000 common shares at $15/share. The company is developing intranasal etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT). The intranasal calcium channel antagonist, also known … [Read more...] about Milestone Pharmaceuticals raises $82.5 million in IPO
Vectura awarded $89.7 million in Ellipta patent infringement suit
According to Vectura, a jury has found that US sales of several of GlaxoSmithKline's Ellipta DPIs infringed on Vectura’s US patent 8303991 ("Method of making particles for use in a pharmaceutical composition"). The jury awarded Vectura $89.7 million in damages and found that GSK willfully infringed on the patent, allowing Vectura to ask for enhanced … [Read more...] about Vectura awarded $89.7 million in Ellipta patent infringement suit
3M announces that it is manufacturing authorized generic of Proventil HFA
3M Drug Delivery Systems has announced that it is manufacturing the authorized generic of Proventil HFA that was recently launched by Par Pharmaceutical. Proventil HFA, which is also manufactured by 3M, is marketed by Merck. 3M DDS Global Business Leader Keith O-Connor commented, “3M Drug Delivery Systems is proud to work with Par to offer patients a lower list … [Read more...] about 3M announces that it is manufacturing authorized generic of Proventil HFA
Satsuma Pharmaceuticals raises $62 million for development of intranasal DHE
Satsuma Pharmaceuticals said that it has raised $62 million in Series B financing that will be used for Phase 3 development of its STS101 intranasal dry powder dihydroergotamine (DHE) for the treatment of migraines. Satsuma was spun off from SNBL in 2017 specifically to develop STS101 and at the time raised $12 million in Series A financing. Earlier this year, the … [Read more...] about Satsuma Pharmaceuticals raises $62 million for development of intranasal DHE
Boehringer Ingelheim completes expansion of Respimat manufacturing facilities
Boehringer Ingelheim said recently that it has completed a €105 million expansion of its facilities in Dortmund and Ingelheim, Germany to increase manufacturing capacity for its Respimat soft mist inhaler. The company said that the expansion has been completed in time to support its launch of a next generation Respimat in Europe this year. The new Respimat is … [Read more...] about Boehringer Ingelheim completes expansion of Respimat manufacturing facilities
FDA approves Akorn’s ANDA for fluticasone propionate nasal spray
Akorn announced that the FDA has approved an ANDA for fluticasone propionate nasal spray submitted by Hi Tech Pharmacal, which was acquired by Akorn in 2014. The nasal spray is a generic of GSK's Flonase, which was approved for OTC sales in the US in 2014. Akorn President and CEO Douglas Boothe said, “We are excited to add to our fluticasone franchise and look … [Read more...] about FDA approves Akorn’s ANDA for fluticasone propionate nasal spray